Internal Reference Number: FOI_7420
Date Request Received: 11/09/2023 00:00:00
Date Request Replied To: 27/09/2023 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in Dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: 鈥� Adalimumab - Humira 鈥� Adalimumab Biosimilar 鈥� Apremilast 鈥� Bimekizumab 鈥� Brodalumab 鈥� Certolizumab 鈥� Deucravacitinib 鈥� Dimethyl fumarate 鈥� Etanercept - Enbrel 鈥� Etanercept Biosimilar 鈥� Guselkumab 鈥� Infliximab - Remicade 鈥� Infliximab Biosimilar 鈥� Ixekizumab 鈥� Risankizumab 鈥� Secukinumab 鈥� Tildrakizumab 鈥� Ustekinumab | |
| Answer To Question 1: 鈥� Adalimumab 鈥� Humira <5 鈥� Adalimumab Biosimilar 22 鈥� Apremilast <5 鈥� Bimekizumab <5 鈥� Brodalumab 6 鈥� Certolizumab <5 鈥� Deucravacitinib 0 鈥� Dimethyl fumarate 0 鈥� Etanercept 鈥� Enbrel 0 鈥� Etanercept Biosimilar 0 鈥� Guselkumab 10 鈥� Infliximab 鈥� Remicade 0 鈥� Infliximab Biosimilar 0 鈥� Ixekizumab <5 鈥� Risankizumab 6 鈥� Secukinumab <5 鈥� Tildrakizumab 6 鈥� Ustekinumab 15 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following: 鈥� Ciclosporin 鈥� Methotrexate - any form and strength 鈥� Methotrexate injections 15mg and above | |
| Answer To Question 2: 鈥� Ciclosporin <5 鈥� Methotrexate - any form and strength 11 鈥� Methotrexate injections 15mg and above <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
